AMGN Jan 2024 320.000 call

OPR - OPR Prezzo differito. Valuta in USD.
0,6600
+0,2700 (+69,23%)
Al 01:50PM EDT. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente0,3900
Aperto0,6600
Denaro0,0800
Lettera0,6600
Prezzo d'esercizio320,00
Scadenza2024-01-19
Min-Max giorno0,6600 - 0,6600
Contratto - Min-MaxN/D
Volume1
Open Interest162
  • GlobeNewswire

    Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

    Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery